The presentation will review 1) GLP-1 receptor agonists and their pharmacology, 2) The emerging evidence base to support their use in treating substance use disorders, and 3) research underway to study their use to treatment substance use disorders.
Continuing Medical Education (CME) Credits Available
Participants in this program may earn the following CME credits:
✔ 1 AOA Category 1-A Credit✔ 1 AMA PRA Category 1 Credit™ (Approval Anticipated)✔ 1 AAPA Category 1 CME Credit (Approval Anticipated)✔ 1 Nurses CNE Credit (Approval Anticipated)
Earn valuable continuing education credits while enhancing your professional knowledge!
Dr Joji Suzuki is the founding Director of the Division of Addiction Psychiatry in the Department of Psychiatry, Brigham and Women's Hospital (BWH), and an Associate Professor of Psychiatry at Harvard Medical School (HMS). He is board certified in Psychiatry, Addiction Psychiatry and Addiction Medicine, and practices as an inpatient addiction consultant at BWH. Over the course of his career, he has successfully launched numerous treatment programs including a comprehensive outpatient dual diagnosis addiction clinic at Brigham and Women's Faulkner Hospital, and a low-barrier, low-threshold, harm-reduction Bridge Clinic at BWH. He is the inaugural Program Director for the BWH Addiction Medicine Fellowship program, and continues to be very active in medical student, resident, and fellow education. He has received NIH funding continuously since 2017, having completed a K23 Career Development Award to receive training in conducting clinical trials with an emphasis on research to improve the care of hospitalized patients. He is now a principal investigator on multiple NIH funded clinical trials to evaluate novel pharmacologic and psychosocial treatments primarily for opioid and alcohol use disorders.